頁面路徑選單
- 首頁
- 市場技術報告
- 生命科學
- 生物科技 & 生物化學
- 報告資訊
Next Generation Sequencing (NGS) Market Size & Forecast By Application (Oncology, Reproductive Health), By Technology (Targeted Sequencing), By Workflow (Data Analysis), By end-use (Academic & Clinical Research), And Trend Analysis, 2014 - 2025
出 版 商：Grand View Research
出版日期：2017/01/10
頁 數：230頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The global next generation sequencing market is anticipated to reach USD 21.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing coverage of NGS is expected to drive use of precision medicine in oncology from research based setting to clinical cancer setting. Commercial payers are also engaged in reviewing the existing and novel tests in order to establish appropriate medical necessity criteria for their clinical and medical policies.
Moreover, improved understanding of the genetic markers of virulence and resistance provided by next generation sequencing is expected to drive demand of the technology in infectious disease diagnosis.
Further Key Findings from the Report suggest:
Oncology accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program.
Targeted resequencing dominated the market owing to its associated benefits such as implementation of the technique such as lower turnaround time and more manageable data sets.
Academic usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance.
Higher adoption of this technology and platforms in university projects is expected to support the estimated share.
Asia Pacific is estimated to witness the fastest growth over the forecast period owing to expected routing of a considerable portion of whole genome sequencing requirements herein.
Key players operating in the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore Technologies Ltd.
Endeavors adopted by participants are such as acquisition of Enzymatics by Qiagen acquired solutions in order to enhance the product portfolio with respect to reagents needed in preparatory steps.
Moreover, improved understanding of the genetic markers of virulence and resistance provided by next generation sequencing is expected to drive demand of the technology in infectious disease diagnosis.
Further Key Findings from the Report suggest:
Oncology accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program.
Targeted resequencing dominated the market owing to its associated benefits such as implementation of the technique such as lower turnaround time and more manageable data sets.
Academic usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance.
Higher adoption of this technology and platforms in university projects is expected to support the estimated share.
Asia Pacific is estimated to witness the fastest growth over the forecast period owing to expected routing of a considerable portion of whole genome sequencing requirements herein.
Key players operating in the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore Technologies Ltd.
Endeavors adopted by participants are such as acquisition of Enzymatics by Qiagen acquired solutions in order to enhance the product portfolio with respect to reagents needed in preparatory steps.
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region Based Segment Share Calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Next Generation Sequencing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Exponentially decreasing costs for genetic sequencing
3.1.1.2 Development of companion diagnostics and personalized medicine
3.1.1.3 Rise in competition amongst prominent market entities
3.1.1.4 Rising clinical opportunity for NGS technology
3.1.1.5 Introduction of technological advancements in cloud computing and data integration
3.1.1.6 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
3.1.1.7 Increasing prevalence of cancer
3.1.2 Market Restraint Analysis
3.1.2.1 Lack of computational efficiency for data management
3.1.2.2 Non-value based NGS reimbursement policy and regulation status
3.1.2.3 Challenges associated with NGS implementation
3.2 Penetration & Growth Prospect Mapping for Applications, 2015
3.3 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2015
3.4 Next Generation Sequencing Platform Positioning
3.4.1 Major Sequencing Platforms Compared - Applications
3.4.2 Major Sequencing Platforms Compared - Specifications
3.5 Next Generation Sequencing Platform Penetration Mapping, 2015
3.6 Next Generation Sequencing Company Market Share Analysis, 2015
3.7 Next Generation Sequencing Reimbursement Environment
3.7.1 Gap fill approach for reimbursement of NGS tests
3.7.2 Role of the commercial payers
3.7.2.1 Payer perspectives for developing coverage policy for Next Generation Tumor Sequencing Panels (NGTS)
3.7.3 Role of diagnostic laboratories and pathology centres
3.8 Next Generation Sequencing Regulatory Environment
3.9 Next Generation Sequencing - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.10 Industry Analysis - Porter’s
Chapter 4 Next Generation Sequencing Market Application Estimates & Trend Analysis
4.1 Next Generation Sequencing Market: Application Movement Analysis
4.2 Oncology
4.2.1 Global oncology market, 2014 - 2025 (USD Million)
4.3 Clinical Investigation
4.3.1 Global clinical investigation market, 2014 - 2025 (USD Million)
4.3.2 Infectious diseases
4.3.2.1 Global infectious diseases market, 2014 - 2025 (USD Million)
4.3.3 Inherited diseases
4.3.3.1 Global inherited diseases market, 2014 - 2025 (USD Million)
4.3.4 Idiopathic diseases
4.3.4.1 Global idiopathic diseases market, 2014 - 2025 (USD Million)
4.3.5 Non-communicable/other diseases
4.3.5.1 Global non-communicable/other diseases market, 2014 - 2025 (USD Million)
4.4 Reproductive Health
4.4.1 Global reproductive health market, 2014 - 2025 (USD Million)
4.4.2 NIPT
4.4.2.1 Global NIPT market, 2014 - 2025 (USD Million)
4.4.3 PGT
4.4.3.1 Global NGS PGT market, 2014 - 2025 (USD Million)
4.4.4 New-born/genetic screening
4.4.4.1 Global newborn/genetic screening market, 2014 - 2025 (USD Million)
4.5 HLA Typing/Immune System Monitoring
4.5.1 Global HLA typing/immune system monitoring market, 2014 - 2025 (USD Million)
4.6 Metagenomics, Epidemiology & Drug Development
4.6.1 Global metagenomics, epidemiology & drug development market, 2014 - 2025 (USD Million)
4.7 Agrigenomics & Forensics
4.7.1 Global agrigenomics & forensics market, 2014 - 2025 (USD Million)
4.8 Consumer Genomics
4.8.1 Global consumer genomics market, 2014 - 2025 (USD Million)
Chapter 5 Next Generation Sequencing Market Technology Estimates & Trend Analysis
5.1 Next Generation Sequencing Market: Technology Movement Analysis
5.2 Whole Genome Sequencing
5.2.1 Global whole genome sequencing market, 2014 - 2025 (USD Million)
5.3 Whole Exome Sequencing
5.3.1 Global whole exome sequencing market, 2014 - 2025 (USD Million)
5.4 Targeted Sequencing & Resequencing
5.4.1 Global targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
5.4.2 DNA based targeted sequencing & resequencing
5.4.2.1 Global DNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
5.4.3 RNA based targeted sequencing & resequencing
5.4.3.1 Global RNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
Chapter 6 Next Generation Sequencing Market Workflow Estimates & Trend Analysis
6.1 Next Generation Sequencing Market: Workflow Movement Analysis
6.2 Pre-Sequencing
6.2.1 Global pre-sequencing market, 2014 - 2025 (USD Million)
6.2.2 NGS library preparation kits
6.2.2.1 Global NGS library preparation kits market, 2014 - 2025 (USD Million)
6.2.3 NGS semi-automated library preparation
6.2.3.1 Global NGS semi-automated library preparation market, 2014 - 2025 (USD Million)
6.2.4 NGS automated library preparation
6.2.4.1 Global NGS automated library preparation market, 2014 - 2025 (USD Million)
6.2.5 Clonal amplification
6.2.5.1 Global clonal amplification market, 2014 - 2025 (USD Million)
6.3 Sequencing
6.3.1 Global sequencing market, 2014 - 2025 (USD Million)
6.4 Data Analysis
6.4.1 Global data analysis market, 2014 - 2025 (USD Million)
6.4.2 NGS primary data analysis
6.4.2.1 Global NGS primary data analysis market, 2014 - 2025 (USD Million)
6.4.3 NGS secondary data analysis
6.4.3.1 Global NGS secondary data analysis market, 2014 - 2025 (USD Million)
6.4.4 NGS tertiary data analysis
6.4.4.1 Global NGS tertiary data analysis services market, 2014 - 2025 (USD Million)
Chapter 7 Next Generation Sequencing Market End-use Estimates & Trend Analysis
7.1 Next Generation Sequencing Market: End-Use Movement Analysis
7.2 Academic Research
7.2.1 Global academic research market, 2014 - 2025 (USD Million)
7.3 Clinical Research
7.3.1 Global clinical research market, 2014 - 2025 (USD Million)
7.4 Hospitals & Clinics
7.4.1 Global hospitals & clinics market2014 - 2025 (USD Million)
7.5 Pharma & Biotech Entities
7.5.1 Global pharma & biotech entities market, 2014 - 2025 (USD Million)
7.6 Other Users
7.6.1 Global other users market, 2014 - 2025 (USD Million)
Chapter 8 Next Generation Sequencing Market Regional Estimates & Trend Analysis, by Service Type, Sector & Application
8.1 Next Generation Sequencing Market Share By Region, 2015 & 2025
8.2 North America
8.2.1 North America next generation sequencing market, 2014 - 2025 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. next generation sequencing market, 2014 - 2025 (USD Million)
8.2.3 Canada.
8.2.3.1 Canada next generation sequencing market, 2014 - 2025 (USD Million)
8.3 Europe
8.3.1 Europe next generation sequencing market, 2014 - 2025 (USD Million)
8.3.2 Germany
8.3.2.1 Germany next generation sequencing market, 2014 - 2025 (USD Million)
8.3.3 UK
8.3.3.1 UK next generation sequencing market, 2014 - 2025 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific next generation sequencing market, 2014 - 2025 (USD Million)
8.4.2 Japan
8.4.2.1 Japan next generation sequencing market, 2014 - 2025 (USD Million)
8.4.3 China
8.4.3.1 China next generation sequencing market, 2014 - 2025 (USD Million)
8.5 Latin America
8.5.1 Latin America next generation sequencing market, 2014 - 2025 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil next generation sequencing market, 2014 - 2025 (USD Million)
8.6 Middle East & Africa
8.6.1 Middle East & Africa next generation sequencing market, 2014 - 2025 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa next generation sequencing market, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Illumina, Inc.
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Roche Sequencing (454 Life Sciences)
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Agilent Technologies
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 PierianDx
9.3.4.1 Company Overview
9.3.4.1.1 Tute Genomics
9.3.4.1.2 Knome Inc.
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Genomatix GmbH
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GATC Biotech Ag
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Oxford Nanopore Technologies
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Macrogen Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Thermo Fisher Scientific, Inc.
9.3.9.1 Company Overview
9.3.9.1.1 Life Technologies Corp.
9.3.9.2 Financial Performance
9.3.9.3 Financial Performance
9.3.9.4 Product Benchmarking
9.3.9.5 Strategic Initiatives
9.3.10 DNASTAR Inc.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Biomatters Ltd.
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Qiagen NV
9.3.12.1 Company Overview
9.3.12.1.1 Ingenuity
9.3.12.1.2 CLC Bio
9.3.12.2 Financial Performance
9.3.12.3 Financial Performance
9.3.12.4 Product Benchmarking
9.3.12.5 Strategic Initiatives
9.3.13 BGI
9.3.13.1 Company Overview
9.3.13.1.1 Complete Genomics Incorporated
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 Perkin Elmer, Inc.
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 Pacific Biosciences of California, Inc
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Partek, Inc.
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 Bio-Rad Laboratories, Inc.
9.3.17.1 Company Overview
9.3.17.2 GnuBIO
9.3.17.3 Financial Performance
9.3.17.4 Product Benchmarking
9.3.17.5 Strategic Initiatives
9.3.18 Myriad Genetics
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 Hologic, Inc. (Gen-Probe Incorporated)
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region Based Segment Share Calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Next Generation Sequencing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Exponentially decreasing costs for genetic sequencing
3.1.1.2 Development of companion diagnostics and personalized medicine
3.1.1.3 Rise in competition amongst prominent market entities
3.1.1.4 Rising clinical opportunity for NGS technology
3.1.1.5 Introduction of technological advancements in cloud computing and data integration
3.1.1.6 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
3.1.1.7 Increasing prevalence of cancer
3.1.2 Market Restraint Analysis
3.1.2.1 Lack of computational efficiency for data management
3.1.2.2 Non-value based NGS reimbursement policy and regulation status
3.1.2.3 Challenges associated with NGS implementation
3.2 Penetration & Growth Prospect Mapping for Applications, 2015
3.3 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2015
3.4 Next Generation Sequencing Platform Positioning
3.4.1 Major Sequencing Platforms Compared - Applications
3.4.2 Major Sequencing Platforms Compared - Specifications
3.5 Next Generation Sequencing Platform Penetration Mapping, 2015
3.6 Next Generation Sequencing Company Market Share Analysis, 2015
3.7 Next Generation Sequencing Reimbursement Environment
3.7.1 Gap fill approach for reimbursement of NGS tests
3.7.2 Role of the commercial payers
3.7.2.1 Payer perspectives for developing coverage policy for Next Generation Tumor Sequencing Panels (NGTS)
3.7.3 Role of diagnostic laboratories and pathology centres
3.8 Next Generation Sequencing Regulatory Environment
3.9 Next Generation Sequencing - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.10 Industry Analysis - Porter’s
Chapter 4 Next Generation Sequencing Market Application Estimates & Trend Analysis
4.1 Next Generation Sequencing Market: Application Movement Analysis
4.2 Oncology
4.2.1 Global oncology market, 2014 - 2025 (USD Million)
4.3 Clinical Investigation
4.3.1 Global clinical investigation market, 2014 - 2025 (USD Million)
4.3.2 Infectious diseases
4.3.2.1 Global infectious diseases market, 2014 - 2025 (USD Million)
4.3.3 Inherited diseases
4.3.3.1 Global inherited diseases market, 2014 - 2025 (USD Million)
4.3.4 Idiopathic diseases
4.3.4.1 Global idiopathic diseases market, 2014 - 2025 (USD Million)
4.3.5 Non-communicable/other diseases
4.3.5.1 Global non-communicable/other diseases market, 2014 - 2025 (USD Million)
4.4 Reproductive Health
4.4.1 Global reproductive health market, 2014 - 2025 (USD Million)
4.4.2 NIPT
4.4.2.1 Global NIPT market, 2014 - 2025 (USD Million)
4.4.3 PGT
4.4.3.1 Global NGS PGT market, 2014 - 2025 (USD Million)
4.4.4 New-born/genetic screening
4.4.4.1 Global newborn/genetic screening market, 2014 - 2025 (USD Million)
4.5 HLA Typing/Immune System Monitoring
4.5.1 Global HLA typing/immune system monitoring market, 2014 - 2025 (USD Million)
4.6 Metagenomics, Epidemiology & Drug Development
4.6.1 Global metagenomics, epidemiology & drug development market, 2014 - 2025 (USD Million)
4.7 Agrigenomics & Forensics
4.7.1 Global agrigenomics & forensics market, 2014 - 2025 (USD Million)
4.8 Consumer Genomics
4.8.1 Global consumer genomics market, 2014 - 2025 (USD Million)
Chapter 5 Next Generation Sequencing Market Technology Estimates & Trend Analysis
5.1 Next Generation Sequencing Market: Technology Movement Analysis
5.2 Whole Genome Sequencing
5.2.1 Global whole genome sequencing market, 2014 - 2025 (USD Million)
5.3 Whole Exome Sequencing
5.3.1 Global whole exome sequencing market, 2014 - 2025 (USD Million)
5.4 Targeted Sequencing & Resequencing
5.4.1 Global targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
5.4.2 DNA based targeted sequencing & resequencing
5.4.2.1 Global DNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
5.4.3 RNA based targeted sequencing & resequencing
5.4.3.1 Global RNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
Chapter 6 Next Generation Sequencing Market Workflow Estimates & Trend Analysis
6.1 Next Generation Sequencing Market: Workflow Movement Analysis
6.2 Pre-Sequencing
6.2.1 Global pre-sequencing market, 2014 - 2025 (USD Million)
6.2.2 NGS library preparation kits
6.2.2.1 Global NGS library preparation kits market, 2014 - 2025 (USD Million)
6.2.3 NGS semi-automated library preparation
6.2.3.1 Global NGS semi-automated library preparation market, 2014 - 2025 (USD Million)
6.2.4 NGS automated library preparation
6.2.4.1 Global NGS automated library preparation market, 2014 - 2025 (USD Million)
6.2.5 Clonal amplification
6.2.5.1 Global clonal amplification market, 2014 - 2025 (USD Million)
6.3 Sequencing
6.3.1 Global sequencing market, 2014 - 2025 (USD Million)
6.4 Data Analysis
6.4.1 Global data analysis market, 2014 - 2025 (USD Million)
6.4.2 NGS primary data analysis
6.4.2.1 Global NGS primary data analysis market, 2014 - 2025 (USD Million)
6.4.3 NGS secondary data analysis
6.4.3.1 Global NGS secondary data analysis market, 2014 - 2025 (USD Million)
6.4.4 NGS tertiary data analysis
6.4.4.1 Global NGS tertiary data analysis services market, 2014 - 2025 (USD Million)
Chapter 7 Next Generation Sequencing Market End-use Estimates & Trend Analysis
7.1 Next Generation Sequencing Market: End-Use Movement Analysis
7.2 Academic Research
7.2.1 Global academic research market, 2014 - 2025 (USD Million)
7.3 Clinical Research
7.3.1 Global clinical research market, 2014 - 2025 (USD Million)
7.4 Hospitals & Clinics
7.4.1 Global hospitals & clinics market2014 - 2025 (USD Million)
7.5 Pharma & Biotech Entities
7.5.1 Global pharma & biotech entities market, 2014 - 2025 (USD Million)
7.6 Other Users
7.6.1 Global other users market, 2014 - 2025 (USD Million)
Chapter 8 Next Generation Sequencing Market Regional Estimates & Trend Analysis, by Service Type, Sector & Application
8.1 Next Generation Sequencing Market Share By Region, 2015 & 2025
8.2 North America
8.2.1 North America next generation sequencing market, 2014 - 2025 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. next generation sequencing market, 2014 - 2025 (USD Million)
8.2.3 Canada.
8.2.3.1 Canada next generation sequencing market, 2014 - 2025 (USD Million)
8.3 Europe
8.3.1 Europe next generation sequencing market, 2014 - 2025 (USD Million)
8.3.2 Germany
8.3.2.1 Germany next generation sequencing market, 2014 - 2025 (USD Million)
8.3.3 UK
8.3.3.1 UK next generation sequencing market, 2014 - 2025 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific next generation sequencing market, 2014 - 2025 (USD Million)
8.4.2 Japan
8.4.2.1 Japan next generation sequencing market, 2014 - 2025 (USD Million)
8.4.3 China
8.4.3.1 China next generation sequencing market, 2014 - 2025 (USD Million)
8.5 Latin America
8.5.1 Latin America next generation sequencing market, 2014 - 2025 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil next generation sequencing market, 2014 - 2025 (USD Million)
8.6 Middle East & Africa
8.6.1 Middle East & Africa next generation sequencing market, 2014 - 2025 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa next generation sequencing market, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Illumina, Inc.
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Roche Sequencing (454 Life Sciences)
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Agilent Technologies
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 PierianDx
9.3.4.1 Company Overview
9.3.4.1.1 Tute Genomics
9.3.4.1.2 Knome Inc.
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Genomatix GmbH
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GATC Biotech Ag
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Oxford Nanopore Technologies
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Macrogen Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Thermo Fisher Scientific, Inc.
9.3.9.1 Company Overview
9.3.9.1.1 Life Technologies Corp.
9.3.9.2 Financial Performance
9.3.9.3 Financial Performance
9.3.9.4 Product Benchmarking
9.3.9.5 Strategic Initiatives
9.3.10 DNASTAR Inc.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Biomatters Ltd.
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Qiagen NV
9.3.12.1 Company Overview
9.3.12.1.1 Ingenuity
9.3.12.1.2 CLC Bio
9.3.12.2 Financial Performance
9.3.12.3 Financial Performance
9.3.12.4 Product Benchmarking
9.3.12.5 Strategic Initiatives
9.3.13 BGI
9.3.13.1 Company Overview
9.3.13.1.1 Complete Genomics Incorporated
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 Perkin Elmer, Inc.
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 Pacific Biosciences of California, Inc
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Partek, Inc.
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 Bio-Rad Laboratories, Inc.
9.3.17.1 Company Overview
9.3.17.2 GnuBIO
9.3.17.3 Financial Performance
9.3.17.4 Product Benchmarking
9.3.17.5 Strategic Initiatives
9.3.18 Myriad Genetics
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 Hologic, Inc. (Gen-Probe Incorporated)
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives
